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ABSTRACT Over 80% of travelers from the United Kingdom to the Indian subcontinent
acquire CTX-M-producing Escherichia coli (CTX-M-EC), but the mechanism of CTX-M-EC ac-
quisition is poorly understood. We aimed to investigate the dynamics of CTX-M-EC ac-
quisition in healthy travelers and how this relates to populations of non-CTX-M-EC in the
fecal microbiome. This is a prospective observational study of healthy volunteers travel-
ing from the United Kingdom to South Asia. Fecal samples were collected pre- and
post-travel at several time points up to 12months post-travel. A toothpicking experi-
ment was used to determine the proportion of cephalosporin-sensitive E. coli in fecal
samples containing CTX-M-EC. MLST and SNP type of pre-travel and post-travel E. coli
were deduced by WGS. CTX-M-EC was acquired by 89% (16/18) of volunteers. Polyclonal
acquisition of CTX-M-EC was seen in 8/15 volunteers (all had 3 STs across post-travel
samples), suggesting multiple acquisition events. Indistinguishable CTX-M-EC clones
(zero SNPs apart) are detectable in serial fecal samples up to 7months after travel, indi-
cating stable maintenance in the fecal microbiome on return to the United Kingdom in
the absence of selective pressure. CTX-M-EC-containing samples were often co-colonized
with novel, non-CTX-M strains after travel, indicating that acquisition of non-CTX-M-EC
occurs alongside CTX-M-EC. The same pre-travel non-CTX-M strains (10 SNPs apart)
were found in post-travel fecal samples after CTX-M-EC had been lost, suggesting return
of the fecal microbiome to the pre-travel state and long-term persistence of minority
strains in travelers who acquire CTX-M-EC.
IMPORTANCE Escherichia coli strains which produce CTX-M extended-spectrum
beta-lactamases are endemic as colonizers of humans and in the environment in
South Asia. This study demonstrates that acquisition of CTX-M-producing E. coli
(CTX-M-EC) in travelers from the United Kingdom to South Asia is polyclonal, which
is likely due to multiple acquisition events from contaminated food and drinking wa-
ter during travel. CTX-M-EC frequently persists in the fecal microbiome for at least
1 year after acquisition, often alongside newly acquired non-CTX-M E. coli strains. In
travelers who acquire CTX-M-EC, pre-travel non-CTX-M E. coli remains as a minority
population in the gut until the CTX-M-EC strains are lost. The non-CTX-M strains are
then reestablished as the predominant E. coli population. This study has shed light
on the dynamics of CTX-M-EC acquisition, colonization, and loss after travel. Future
work involving manipulation of nonvirulent resident E. coli could be used to prevent
colonization with antibiotic-resistant E. coli.
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The global prevalence of CTX-M-producing Escherichia coli (CTX-M-EC) is rising,thereby increasing the use of carbapenem antibiotics and acting as a driver for the
emergence of carbapenemase-producing Enterobacteriaceae (CPE) (1). Anthropogenic
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factors such as low levels of sanitation, poor standards of animal husbandry, and the
use of antibiotics in humans and animals all contribute to the high prevalence of
CTX-M-EC in low and middle income countries (2). In the United Kingdom, the preva-
lence of fecal carriage of CTX-M-producing Enterobacteriaceae remains low at 7.3% (3).
International travel plays a key role in the spread of antibiotic-resistant bacteria
carried in the human gut (4), and the acquisition of CTX-M-EC by travelers who visit
countries with high levels of CTX-M producers in the environment is a well-recognized
phenomenon (5, 6). In particular, travel to the WHO Southeast Asia region, which
includes densely populated countries such as India and Bangladesh, presents the
highest risk for acquisition of CTX-M-producing Enterobacteriaceae (6). Although acqui-
sition rates by world region, and risk factors for acquisition, have been investigated
previously, the dynamics of colonization by ESBL-producing E. coli and non-ESBL-
producing E. coli have not.
We undertook a prospective observational cohort study to explore the dynamics of
acquisition of CTX-M-EC in travelers from the United Kingdom to South Asia. We used
whole-genome sequencing (WGS) to characterize strains before and after travel, pro-
viding a novel insight into the changes in populations of E. coli, including the role of
non-CTX-M cephalosporin-sensitive E. coli in the human fecal microbiome of returning
travelers.
RESULTS AND DISCUSSION
Travelers to South Asia have a high CTX-M-EC acquisition rate. Twenty-two
volunteers provided informed consent to take part in the study. Three volunteers
withdrew from the study before providing samples (Fig. 1). The mean and median ages
of volunteers were 34 and 30 years, respectively. After screening volunteer stool
samples using selective culture and PCR, 18/19 were blaCTX-M negative before travel.
The single volunteer found to be carrying CTX-M-15-producing E. coli before travel had
been to India in the previous 6 months, which is a known risk factor for colonization in
the United Kingdom (3, 7). The primary destinations visited by volunteers were India
(68%; 13/19) and Sri Lanka (31%; 6/19). The mean travel duration for all countries was
27 days (median, 21 days). The shortest duration of travel by any volunteer was 10 days,
which still resulted in CTX-M-EC acquisition. The majority of volunteers experienced
symptoms of gastroenteritis at some point during their trip (68%; 13/19) (Table 1).
After travel, blaCTX-M had been acquired by 16/18 (89%) volunteers (Fig. 1). Two
volunteers acquired E. coli producing both CTX-M-14 and CTX-M-15; one volunteer
acquired only CTX-M-14-producing E. coli, while the remaining thirteen acquired only
FIG 1 Outline of volunteers recruited and excluded from study with CTX-M-EC acquisition rate
post-travel.
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CTX-M-15-producing E. coli (Table 1). Speciﬁc blaCTX-M genotypes are often strongly
associated with speciﬁc regions; in particular, CTX-M producers in India are almost
entirely comprised of blaCTX-M-15, whereas in China, blaCTX-M-14 is the predominant
genotype (2). Most volunteers traveled to India; therefore, the high acquisition rate of
CTX-M-15-producing E. coli is unsurprising. Volunteers 4 and 19, who acquired
blaCTX-M-14, traveled to China and/or Sri Lanka, where blaCTX-M-14-producing E. coli
strains are common (8, 9). Volunteer 16 also acquired blaCTX-M-14-producing E. col, but
traveled only to India, where blaCTX-M-14 is a rare genotype; however, this individual traveled
widely (Kerala, Karnataka, New Delhi, and Uttarakhand). He also worked in a hospital in
Bangalore as a volunteer for 4weeks, which may have resulted in contact with travelers or
residents from areas of the world where CTX-M-14 is common, such as China.
The largest traveler study to date, which investigated 2,001 healthy volunteers (the
COMBAT study), found that the country visited with the highest ESBL-EC acquisition
rate was India: 89% (70/79) of those who traveled from The Netherlands to India
acquired ESBL-producing E. coli (6). Other traveler studies have also shown high
acquisition rates of ESBL-producing Enterobacteriaceae in those who visit India: pro-
spective studies report acquisition rates of 73% (66/90 participants) (10), 85% (53/62
participants) (11), and 87% (59/68 participants) (12). After WGS and bioinformatic
screening of contigs, none of our post-travel isolates carried carbapenemase genes.
This is consistent with the COMBAT study, which reported the rate of CPE acquisition
in returning travelers as 1% (6).
CTX-M-EC acquisition is polyclonal. CTX-M-producing E. coli acquired during
travel came from a wide range of sequence types (STs) and phylogenetic groups (Fig. 2),
in keeping with previous studies (12–16). Among volunteers in our study, we found that
11/15 (73%) acquired CTX-M-EC belonging to phylogenetic group (PG) A. Other com-
mon PGs were PG-D (6/15 volunteers, 40%), PG-B2 (5/15, 33%), and PG-B1 (4/15, 27%).
ST131 was the majority ST in PG-B2-positive volunteers (4/5 volunteers), with the
remaining volunteer carrying ST1193. In terms of E. coli pathogenicity, PG-B2 and PG-D
are often extraintestinal pathogenic E. coli (ExPEC), causing urinary sepsis and bacte-
remia, whereas PG-A and PG-B1 usually lack the pathogenicity genes conferring
extraintestinal virulence (17). Our ﬁndings are in keeping with previous studies which
found a predominance of PG-A in travel-acquired strains (13, 18). Moreover, CTX-M-EC
strains belonging to PG-A, PG-D, and PG-B1 were previously found to be commonly
acquired after travel (13).
TABLE 1 Outcomes for 18 volunteers before versus after travela
Volunteer Destination(s)
Pre-travel
CTX-M
Post-travel
CTX-M
CTX-M
genotype Risk factor(s)
Duration of
carriage
1 India No Yes 15 1–3 wk
3 India No Yes 15 9 mo*
4 Sri Lanka, Cyprus No Yes 14 and 15 G 5 mo*
5 India No Yes 15 G 12 mo*
6 India No Yes 15 G 6 wk
7 India No Yes 15 G 2–4 mo
8 India No Yes 15 G and Abx 11 mo*
9 Sri Lanka, India No Yes 15 G 7 mo*
10 Sri Lanka, India No No NA G NA
12 India No Yes 15 G 2–4 mo
15 India No Yes 15 G 1 wk*
16 India No Yes 14 and 15 G 6 mo*
17 India No Yes 15 3–6 wk
18 Sri Lanka, China No No NA G NA
19 Sri Lanka, China No Yes 14 Abx 14 days*
20 India No Yes 15 G 3–4 mo
21 Pakistan No Yes 15 G 1–2 wk
22 Sri Lanka No Yes 15 1–3 wk
aAbbreviations and symbols: “No,” lack of CTX-M by culture, PCR, and WGS; “Yes,” blaCTX-M detected; G,
gastroenteritis symptoms; Abx, antibiotic consumption during travel; *, duration of carriage where a “CTX-
M-free” follow-up fecal sample could not be obtained; NA, not applicable.
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Gut colonization with CTX-M-EC was often polyclonal in those acquiring CTX-M-EC
(8/15 volunteers with sequenced E. coli had 1 MLST producing CTX-M [Table 2 and
see Table S1 in the supplemental material]). The mean number of acquired E. coli STs
per volunteer was 3; 7/15 travelers had 3 E. coli STs with blaCTX-M. The commonest ST
among CTX-M-producing E. coli strains was ST131 (4/15), with other common STs being
ST38 (3/15), ST10 (3/15), and ST43 (3/15).
The only data on the distribution of the E. coli STs in South Asia come from three
centers: Pune (19, 20), Kolkata (21), and Islamabad (22). Roy et al. found that 6/67
isolates causing bacteremia on a neonatal intensive care unit were ST131 using a
PCR-based method: no MLST was carried out (21). Hussain et al. also used a PCR-based
approach only, ﬁnding that 16/23 ESBL-producing E. coli isolates identiﬁed in Pune
were ST131 (19). Ranjan et al. determined the MLST of only 8 clinical isolates from Pune,
India, ﬁnding that 2/8 were E. coli ST131, with no single ST predominating (20). Zahra
et al. surveyed the MLSTs of 110 E. coli isolates sampled from human sewage across
multiple locations in Islamabad, Pakistan (22). Zahra and colleagues found 24 STs, with
FIG 2 Phylogenetic relationships of pre- and post-travel E. coli strains displaying the phylogenetic groups, majority
MLST types, and presence of blaCTX-M. Four hundred eighty-three E. coli strains from 15 volunteers. *, white bars
indicate where phylogenetic group undetermined.
TABLE 2 Pre- and post-travel E. coli from each volunteer indicating CTX-M-EC, non-CTX-M-EC, and toothpicked strainsa
Volunteer
No. of fecal samples E. coli MLST after Illumina sequencing
Pre-travel Post-travel Pre-travel ST Post-travel STb ST of non-CTX-M-EC from toothpicking exptc
1 2 4 131 349, NT, 394, 69, 131
3 3 6 69, 941, 2008 43, 38, 1193, 405 2076, 617, 46 (3/3a), 224 (1/3b), 10 (2/3f)
4 2 5 10 2732, 69, NT, 648
5 1 10 452 38, 405, 131, 48, NT, 10, 6338, 88, 3478
6 3 4 69, 73 450, NT, 2221, 73
7 3 6 10, NT,e 69 10, 6438, NT, 43, 200, 3036, 69
8 2 7 69, 1163, 2712, 10, NT 448, 10, 648, 131 38 (1/8g)
9 3 6 69, 3727, NT 4, 200, 2617, NT 2617d (1/9f)
10 3 4 354 642, 200, 34, NT
12 2 8 1314, 10, 752, 770 43, 1276, 189, 5919, 216 349 (1/12e)
15 2 3 210, 10, NT 167, 52, 10
16 2 5 349 38, 227, 131
17 2 3 NT, 131 450, 43, 131 206 (1/17a)
19 2 1 10 43 7174 (1/19a)
20 2 6 10, 452, NT NT, 162, 131, 226, 405, 10 2797 (1/20a), 10 (1/20b)
22 2 3 2619 226, 607, 2967, 7174
aGray shading indicates data from toothpicking experiments.
bStandard font indicates non-CTX-M; boldface indicates CTX-M-15; italic indicates CTX-M-14.
cText in parentheses, e.g., “(3/3a),” indicates the number of toothpicked colonies which were sequenced, followed by the fecal sample number.
dST2617, non-CTX-M-EC, in fecal sample 9f, is not the same strain as the CTX-M-producing ST2617, also from volunteer 9 feces (after SNP typing).
eNT, non-typeable.
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ST394, ST10, and ST648 predominating, with only 1/110 being ST131 (22). Apart from
ST10, the other dominant STs seen by Zahra et al. were not seen in our study. It is
notable that ST131 was a rare occurrence in the Islamabad sewage network, contrasting
with the prevalence of ST131 CTX-M-EC in our study. This may be due to ST131 E. coli
being an exceptional colonizer of the human fecal microbiome, rather than of the
sewage environment in Islamabad. Due to the paucity of data in South Asia, our study
provides a much-needed “snapshot” of E. coli strains originating from the region.
Dureja et al. obtained fecal samples from 102 healthy adults in Chandigarh, India,
during 2012 to 2013 and used PCR to determine the phylogenetic groups (23). Dureja
and colleagues found that the most common E. coli phylogenetic groups were A (54%,
55/102) and B1 (24%, 24/102), with 9/15 CTX-M-15-producing E. coli strains belonging
to PG-A (23). This dominance of PG-A is in keeping with previous work which showed
that PG-A tends to predominate in the human fecal microbiome in tropical regions
compared to temperate regions (24).
Relatively few studies have assessed the E. coli MLSTs from the human fecal
microbiome identiﬁed after travel, but all found there to be a wide range of ESBL-
producing E. coli MLSTs acquired through travel (12, 13, 15). Pires and colleagues are
the only group to have assessed the colonization with particular E. coli STs before and
after travel, showing that travel from Switzerland to India results in polyclonal coloni-
zation with CTX-M-producing E. coli with a mean of two STs and a range of 1 to 5 (13).
Kuenzli et al. found that in a representative population of 34 CTX-M-EC isolates from an
undescribed number of volunteers acquired after travel to India, there were 24 different
STs (12). Paltansing et al. found 86 different STs from 146 ESBL-producing E. coli isolates
from 133 travelers but did not describe the speciﬁc STs acquired from South Asia or
India (15). In our study, we identiﬁed 26 different STs from 198 post-travel CTX-M-EC
isolates, collected from 15 volunteers (Table S1).
CTX-M-EC clones are maintained after travel. The mean duration of carriage of
CTX-M-EC was 113 days, with a median of 60 days. This carriage duration must be
considered an underestimate, because 8/16 volunteers remained CTX-M-EC carriers at
the last fecal sampling point (Table 1). Thirty-one percent (5/16) of volunteers were
known to be CTX-M-EC positive at 6 months after travel. The volunteers with the
longest duration of carriage of CTX-M-EC were colonized with ST131 (PG-B2)
(11 months, volunteer 8), ST405 (PG-D) (9 months, volunteer 3), and ST648 (PG-B1)
(8 months, volunteer 8). Considering all strains which colonized the fecal microbiome
for the longest duration, there was no predominance of any particular ST or PG.
Arcilla et al. found 11.3% (68/601) were persistently colonized with the same
ESBL-producing organism at 6 months post-travel, with a median post-travel duration
of colonization of 30 days, but did not report a subgroup analysis on the duration of
carriage for 79 travelers who went to India (6). Another study supporting this ﬁnding
was that of Pires et al., who found a 40% colonization rate (6/15 travelers), 6 months
after return from India (13). Ruppé et al. also found that 7.2% (8/111) of ESBL-carriage-
positive travelers were still carriers at 6 months after travel to Asia, with no speciﬁc
country data (11). Moreover, Ruppé et al. reported that travel to Asia is signiﬁcantly
associated with a longer duration of carriage than travel to Africa or Latin America (11).
A more recent Canadian study found that 15/70 (21%) travelers to South Asia who
acquired ESBL-producing E. coli, were still colonized 6 months after return to Canada
(10).
Eight volunteers in our study provided stool samples at two or more time points
after travel. All these volunteers carried CTX-M-EC of the same ST in stool samples at
different time points. By SNP typing, in 8/8 volunteers the isolates found in separate
fecal samples are 10 SNPs apart, suggesting stable colonization with the same strain
over several months (Table 3). Four volunteers had post-travel CTX-M-EC isolates which
were indistinguishable (0 SNPs) between separate post-travel fecal samples collected at
different time points (Table 3).
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TABLE 3 SNP typing of post-travel CTX-M-EC
Straina Sample collection point (days post-travel) MLST Phylogenetic group
3b3 7 1193b B2
3b4 7 11930 B2
3c3 28 11930 B2
3d1 56 119363 B2
3d2 56 119352 B2
3d3 56 11930 B2
3d4 56 119363 B2
4a6 7 69b D
4b1 30 695 D
4b2 30 694 D
4b3 30 694 D
4b4 30 694 D
4c1 49 694 D
4c4 49 694 D
4e1 152 694 D
4e2 152 695 D
4e4 152 694 D
5.2a 4 post-Uzbekistan 38b D
5.2b 4 post-Uzbekistan 382 D
5.2c 4 post-Uzbekistan 382 D
5.2e 4 post-Uzbekistan 382 D
5.2f 4 post-Uzbekistan 382 D
5a1 3 post-India, 35 post-Uzbekistan 48d A
5a2 3 post-India, 35 post-Uzbekistan 4648 A
5a3 3 post-India, 35 post-Uzbekistan 4248 A
5a4 3 post-India, 35 post-Uzbekistan 3948 A
5b1 8 post-India 4848 A
5b3 8 post-India 3348 A
5b4 8 post-India 2648 A
5c4 28 post-India 4648 A
5e3 91 post-India 386 D
5e4 91 post-India 386 D
5f3 183 post-India 1276548 A
8b2 16 10b A
8b3 16 101 A
8b4 16 101 A
8c1 40 102 A
8c2 40 1043 A
8c3 40 102 A
8c4 40 102 A
8d1 58 101 A
8d2 58 1013331 A
8d4 58 1013323 A
9b1 14 261719 F
9b2 14 2617b F
9c1 35 26179 F
9c2 35 26175 F
9c3 35 26177 F
9c4 35 26171 F
9d1 91 26172 F
9d3 91 26172 F
9d4 91 26177 F
9e1 152 26174 F
9e2 152 26170 F
9e3 152 26176 F
9e4 152 26171 F
9f1 210 26173 F
9f2 210 26177 F
9f3 210 26175 F
9f4 210 26174 F
12a1 3 435 A
12a2 3 43b A
12a3 3 430 A
12a4 3 430 A
12b1 21 430 A
12b2 21 430 A
(Continued on next page)
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Given the diversity within the larger STs of E. coli, it is not surprising that we also
found colonization with completely different strains deﬁned by WGS of the same MLST
group. Volunteer 8 carried two ST10 populations after travel which were 13,323 SNPs
apart (Table 3).
Volunteer 5 is particularly notable as being the only volunteer to make a trip outside
South Asia before the trip to India. She ﬁrst traveled to Uzbekistan for 10 days and then
returned to the United Kingdom for 30 days. This was followed by a trip to India for
14 days and then return to the United Kingdom. Volunteer 5 submitted one sample
pre-Uzbekistan (5.1), and no strains found were subsequently isolated (Table S1).
Sample 5.2 was collected 4 days after return from Uzbekistan (CTX-M-EC, ST38), and
sample 5a1 was collected 3 days after the volunteer returned from India (ST48 CTX-
M-EC only). Sample 5e4 was collected 12 weeks after return from India (ST38 CTX-M-EC
only) (Table 3). The ST38 isolates in fecal samples 5.2 and 5e4 are only 6 SNPs different,
suggesting that the same CTX-M-EC strain remained as a colonizer within the fecal
microbiome post-Uzbekistan, during the trip to India, and was again maintained on
return to the United Kingdom (Table 3). An additional ST48 strain (5f3) was identiﬁed
from sample 5f (6 months after returning from India): this strain, 5f3, was 12,765 SNPs
different from the ST48 strains from earlier post-India samples (Table 3). Strain 5f3 is
most likely to be a travel-acquired strain which was not detected in the earlier
post-travel samples.
Pires and colleagues used MLST and repetitive palindromic PCR (RepPCR) to dem-
onstrate that CTX-M-EC strains detected immediately post-travel are detected again at
3 and 6 months post-travel, with the same RepPCR ﬁngerprint (13). However, Pires did
not carry out SNP typing to prove that the same strains are carried over time, nor did
they present the MLST or RepPCR proﬁles of pre-travel non-CTX-M-EC.
TABLE 3 (Continued)
Straina Sample collection point (days post-travel) MLST Phylogenetic group
12b3 21 430 A
12b4 21 431 A
12c1 29 430 A
12c2 29 430 A
12c3 29 430 A
12c4 29 430 A
12d1 56 431 A
12d2 56 433 A
12d3 56 432 A
12d4 56 432 A
12e1b 115 430 A
12e2 115 430 A
12e3 115 431 A
12e4 115 431 A
16b2 40 131b B2
16c1 91 1314 B2
16c2 91 1313 B2
16c4 91 1312 B2
16e1 179 1313 B2
16e2 179 1314 B2
16e3 179 1313 B2
16e4 179 1316 B2
20a3 7 1625 NGc
20a4 7 162b NG
20b1 42 1620 NG
20b2 42 1620 NG
20b3 42 1620 NG
20b4 42 1620 NG
aIsolate naming system: e.g., 3b3, where “3” stands for volunteer 3, “b” stands for the second post-travel
fecal sample, and the following digit “3” stands for the third colony pick from the sample.
bReference strain for SNP comparisons for any given volunteer. SNPs are displayed as superscripts after
the ST.
cNG, no phylogenetic group assigned to the Warwick MLST.
dSecond reference strain where 2 STs are present (volunteer 5). SNPs are displayed as superscripts before
the ST.
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The polyclonal nature of CTX-M-producing E. coli acquisition in our study suggests
multiple acquisition events during travel, which is in keeping with exposure to food and
water supplies contaminated with fecal bacteria. Carriage of the same CTX-M-EC
clones—often for several months after return to the United Kingdom—shows that the
acquired strains are not easily displaced and suggests stable colonization in the fecal
microbiome in the absence of antibiotic selective pressure.
Non-CTX-M-producing E. coli strains acquired during travel co-colonize the GI
tract alongside CTX-M-EC strains after acquisition during travel. To determine
whether fecal samples containing CTX-M-EC co-colonize the fecal microbiome with
CTX-M non-producers, a toothpicking experiment was undertaken with fecal samples
from a representative selection of volunteers (eight) who were CTX-M-EC positive. One
hundred individual colonies from stool culture plates were individually spotted onto
antibiotic-free agar and then onto cefotaxime-containing agar. Picking 100 colonies per
fecal sample allows the isolation of the major and minority E. coli strains in the sample
(25). The cefotaxime-sensitive strains were then tested for the absence of CTX-M-EC
using CTX-M grouping PCR.
The results showed that the proportion of cefotaxime-resistant E. coli in fecal
samples known to contain CTX-M-EC varied considerably between volunteers and at
different time points for the same volunteer (Fig. 3). In fecal samples collected from the
same volunteer that were analyzed using toothpicking over time, the proportion of
cefotaxime-resistant strains did not remain stable (Fig. 3). In 3/4 volunteers for whom
we undertook toothpicking on multiple fecal samples, the proportion of cefotaxime-
resistant strains diminished over time (Fig. 3), probably reﬂecting competition from
non-CTX-M-EC and lack of reexposure to CTX-M-EC through ingestion in the United
Kingdom. In 7/7 cases where non-CTX-M-EC isolates were detected by toothpicking in
stool samples that contained CTX-M-EC, WGS revealed that these strains were not
related to either the endogenous non-CTX-M-EC present before travel or the CTX-M-EC
acquired during travel (Table 2).
The present study is thus the ﬁrst to demonstrate co-colonization of third-
generation-cephalosporin-sensitive E. coli in the fecal microbiome containing CTX-M-
producing strains. There are two possibilities underlying this phenomenon: (i) gut
colonization during travel includes CTX-M producers and CTX-M non-producers and (ii)
the CTX-M non-producers were acquired after return to the United Kingdom and were
detected in stool samples co-colonizing with travel-acquired CTX-M producers. It is also
possible that both scenarios take place. However, in 7/7 toothpicking experiments, the
third-generation-cephalosporin-sensitive E. coli STs detected were different from both
the pre-travel CTX-M-free strains and the post-travel CTX-M producers. Thus, our data
FIG 3 Proportion of cefotaxime-resistant strains in post-travel fecal samples containing CTX-M-EC. Vol.,
volunteer.
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suggest that travel results in acquisition of both CTX-M producers and non-producers
(Table 2), providing further evidence of probable multiple episodes of E. coli ingestion
and colonization via food and drink during travel. Sampling volunteers while overseas,
which was beyond the scope of our study, would be required to conﬁrm this hypoth-
esis. This would allow determination of how long it took for each volunteer to acquire
CTX-M-EC and non-CTX-M E. coli during their trip.
The toothpicking approach was the most effective way in which to (i) determine the
diversity of E. coli strains, including determining the minority strains present in a sample
of 100 colony picks, and (ii) allow linkage of CTX-M carriage or noncarriage with speciﬁc
E. coli STs. Alternative methods, such as the use of shotgun metagenomic sequencing
of fecal samples, would not allow the same resolution for the analysis of E. coli clonal
dynamics as our toothpicking approach, in particular, assigning blaCTX-M genes to
speciﬁc strains. In addition, shotgun metagenomic analysis has relatively low sensitivity
in detecting minority bacterial populations, compared to culture (26).
Pre-travel resident E. coli strains persist as a minority population in the fecal
microbiome. For seventeen volunteers, non-CTX-M-EC populations were sequenced
before and after travel. In the case of seven volunteers who had acquired and then lost
CTX-M-EC, we detected the same non-CTX-M-EC MLSTs before and after travel. We used
SNP typing to deﬁne whether these strains were the same clonal lineage of non-CTX-
M-EC before versus after travel. In 5/7 volunteers we found near-indistinguishable
strains (20 SNPs) before and after travel (Table 4). All ﬁve volunteers also acquired and
lost co-colonizing CTX-M-EC. This is a new ﬁnding: pre-travel E. coli strains are not
completely displaced from the fecal microbiome but are maintained as a minority
population throughout travel and become detectable again as a majority population
after travel (Table 4).
Previous research into the effect of travel on the composition of the fecal micro-
biome using metagenomic sequencing showed that in Swedish travelers going to India
or Central Africa, there is a spike in abundance of the Proteobacteria phylum after travel
(27). Increasing abundance of Proteobacteria may result from low-level inﬂammation as
a result of change in diet, low-level gut inﬂammation due to travel, and gastroenteritis
due to infecting bacteria and parasites (27), therefore allowing colonization with
CTX-M-EC.
A metagenomic study undertaken by David and colleagues showed that the human
fecal microbiome returns to its pre-travel state after perturbation resulting from travel
(28). David et al. sequenced the fecal microbiome over 1 year, in an individual who
traveled from the United States to Southeast Asia for a period of 51 days, and showed
that travel results in a swing to Bacteroidetes and Proteobacteria, which is reversed on
returning to the home environment (28).
A small number of studies have considered the E. coli clonal dynamics of travel-
acquired strains over time (13–15). Pires et al. (13) found 3/15 volunteers who were
CTX-M positive before travel, and in 1/3 cases, the ST648 CTX-M-14-producing strain
found before travel was also detected at 3 months after travel and was presumably the
same pre-travel strain. Similarly, Vading et al. used Rep-PCR to show that four volun-
teers carried the same PG-B2 ESBL-producing Enterobacteriaceae before and after travel
(14). Moreover, Paltansing et al. showed that 4/7 volunteers who were CTX-M positive
pre-travel had the same CTX-M-strain genotype and ST combination detected in fecal
samples after travel (15). Based on the ﬁndings from Pires et al., Vading et al., and
Paltansing et al., it is reasonable to suggest that pre-travel CTX-M-EC strains often
persist throughout the period of travel and are detectable in post-travel fecal samples.
However, unlike the present study, none of these studies did SNP typing of strains nor
did they determine diversity of pre-travel non-ESBL E. coli, so deﬁnitive evidence of
pre-travel strain persistence after travel was not provided. Our study is the ﬁrst to
provide evidence from MLST and SNP typing that indistinguishable cefotaxime-
sensitive strains (non-CTX-M-EC) are present before and after travel to South Asia.
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TABLE 4 SNP comparisons of pre- and post-travel non-CTX-M-producing E. coli for
volunteers with the same MLSTs before and after travel
Volunteer Isolate
Sample collection pointa
(days pre- or post-travel) MLST Phylogenetic group
1 1_1a 10 pre 131b B2
1_1b 10 pre 1315 B2
1_1c 10 pre 1311 B2
1_1d 10 pre 13119 B2
1_2a 5 pre 13117 B2
1_2b 5 pre 13118 B2
1_2c 5 pre 1316 B2
1_e_1 122 post 1313 B2
1_e_2 122 post 1316 B2
1_e_3 122 post 1312 B2
6 6_1c 42 pre 7317 B2
6_1e 42 pre 7314 B2
6_2a 28 pre 7377 B2
6_2b 28 pre 73b B2
6_2c 28 pre 7314 B2
6_2d 28 pre 7322 B2
6_3a 1 pre 7323 B2
6_3b 1 pre 7317 B2
6_3c 1 pre 7327 B2
6_3d 1 pre 7317 B2
6_3e 1 pre 7320 B2
6_3f 1 pre 7388 B2
6c2 42 post 731 B2
6c4 42 post 7330 B2
6d1 180 post 7324 B2
6d2 180 post 7324 B2
6d3 180 post 735 B2
6d4 180 post 7320 B2
7 7_1a 60 pre 10b A
7_1b 60 pre 102 A
7_1c 60 pre 102 A
7_1d 60 pre 101 A
7_1e 60 pre 100 A
7_1f 60 pre 105 A
7_3b 7 pre 102 A
7_3c 7 pre 103 A
7_3d 7 pre 104 A
7_3e 7 pre 102 A
7_3f 7 pre 102 A
7a1 5 post 1018143 A
7b1 10 post 1018141 A
7b2 10 post 1018124 A
8 8.2a 1 pre 10b A
8.2b 1 pre 105 A
8.2d 1 pre 102 A
8.2e 1 pre 1017 A
8.2f 1 pre 101 A
8b2 16 post 1017093 A
8b3 16 post 1017084 A
8b4 16 post 1017085 A
8c1 40 post 1017085 A
8c2 40 post 1017087 A
8c3 40 post 1017084 A
8c4 40 post 1017088 A
8d1 58 post 1017084 A
8d2 58 post 1013306 A
8d4 58 post 1013307 A
8d5 58 post 1017084 A
15 15_1c 28 pre 10b A
15_1d 28 pre 106 A
(Continued on next page)
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Conclusions. This study has conﬁrmed the high rates of acquisition of CTX-M-EC by
travelers from countries of low CTX-M-EC endemicity to areas with high community
prevalence of CTX-M-EC and is the ﬁrst such study to recruit healthy travelers prospec-
tively from the United Kingdom. We show that travelers usually acquire multiple E. coli
sequence types carrying blaCTX-M, the same CTX-M-EC clonal lineages are carried in the
gut after return to the United Kingdom, and the post-travel fecal microbiome often
contains both CTX-M-EC and non-CTX-M-EC.
There are some limitations around the population recruited in this study, leading to
possible selection bias. The volunteers were all university or hospital employees or
students and are not representative of the United Kingdom population with respect to
age or socioeconomic level. In addition, 5/16 travelers who acquired CTX-M-EC did
medical elective placements in hospitals in India or Sri Lanka. Therefore, they may have
acquired strains from these institutions, rather than from community exposure.
A further limitation is that we did not include non-E. coli Enterobacteriaceae in this
study. We found that Klebsiella and Enterobacter species actually made up a very small
number of isolates cultured on the chromogenic agar; therefore, we chose to focus on
the predominant E. coli. It must also be noted that in previous studies, E. coli was the
main carrier of blaCTX-M among the Enterobacteriaceae (3, 6).
It must also be noted that we did not investigate the speciﬁc CTX-M-EC acquisition
events which occurred during travel. This would involve sampling while outside the
United Kingdom and was beyond the scope of the present study.
We have provided novel data on the dynamics of colonization with CTX-M-EC and
non-CTX-M-EC after travel. Our data provides evidence that humans acquire both
CTX-M-EC and non-CTX-M-EC after travel to South Asia, while a minority population of
pre-travel E. coli strains re-emerge as the dominant E. coli population after CTX-M-EC is
TABLE 4 (Continued)
Volunteer Isolate
Sample collection pointa
(days pre- or post-travel) MLST Phylogenetic group
15_2c 14 pre 1010 A
15_2d 14 pre 1054 A
15c1 150 post 109 A
15c2 150 post 107 A
15c3 150 post 1023 A
15c4 150 post 1014 A
17 17_2a 3 pre 131b B2
17_2b 3 pre 13118 B2
17_2c 3 pre 13112 B2
17_2d 3 pre 13111 B2
17_2e 3 pre 13127 B2
17_2f 3 pre 1318 B2
17c1 84 post 13116 B2
17c2 84 post 13129 B2
17c3 84 post 13117 B2
17c4 84 post 13145 B2
20 20_1b 10 pre 1013568 A
20_1c 10 pre 1013553 A
20_2a 4 pre 1014956 A
20bpp 42 post 10b A
20f1 120 post 1010 A
20g1 183 post 1024 A
20g2 183 post 109 A
20g3 183 post 109 A
20g4 183 post 1031 A
aSample collection point includes only fecal samples where the E. coli sequence type displayed for that
volunteer was detected. For the full list of isolates, see Table S1. Boldface indicates pre-travel fecal samples,
and italic indicates post-travel.
bReference strain for SNP comparisons for any given volunteer. SNPs are displayed as superscripts after
the ST.
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lost. The loss of CTX-M-EC after travel, albeit sometimes up to a year post-travel, may
be due to the competition from preexisting non-CTX-M E. coli. The manipulation of
non-pathogenic, non-ESBL-EC in order to displace virulent antibiotic-resistant strains in
community and health care settings (including carbapenemase-producing Enterobac-
teriaceae and mcr-1-producing strains) is an avenue worth exploring in the battle
against the spread of antimicrobial resistance in Enterobacteriaceae.
MATERIALS AND METHODS
Volunteer recruitment and inclusion/exclusion criteria. Volunteers were recruited from the
student and staff members of the University of Birmingham and University Hospitals Birmingham
Heartlands Hospital, using posters and targeted emails and via Twitter in the period March 2015 to June
2016. Individuals planning travel to South Asia contacted E.R.B. by email or telephone, at which point
they were excluded from taking part if they reported previous travel to South Asia in the previous three
months or if they had a signiﬁcant long-term chronic disease. South Asia includes Afghanistan, Bangla-
desh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka (29), but only volunteers planning travel to
Bangladesh, India, Pakistan, and Sri Lanka were encountered. Written informed consent was obtained
from all volunteers who took part.
Laboratory methodology: sample collection, culture, and identiﬁcation. Volunteers were asked
to provide at least 5 g of feces and were asked to provide a specimen as close to the time of sample
submission as possible. Volunteers were then met in person by E.R.B., and samples were stored for no
more than 24 h at 4°C before culture.
The following culture-based ESBL-EC isolation strategies were then undertaken. (i) A sterile swab was
used to inoculate samples onto Oxoid ESBL brilliance agar, which was incubated at 37°C for 24 to 48 h.
(ii) Additional chromogenic agar (Oxoid UTI brilliance agar) supplemented with a cefpodoxime disc
(10 g/ml) was inoculated with serial dilutions of stool culture, to allow isolation of single colonies after
24-h incubation. (iii) Brain heart infusion (BHI) broth supplemented with a cefpodoxime disc (10 g/ml)
was also inoculated with a sterile swab loaded with feces, incubated at 37°C for 24 h. A 10-l loop of the
overnight BHI was then subcultured onto a fresh UTI chromogenic agar plate supplemented with a
cefpodoxime disc and incubated for a further 24 h.
Putative ESBL-EC strains were identiﬁed as blue or pink colonies on ESBL agar, and pink or clear
colonies within the cefpodoxime disc zone (or outside the zone in pre-travel samples) on UTI medium
before and after broth enrichment. Each colony pick was conﬁrmed to be E. coli using matrix-assisted
laser desorption–ionization time of ﬂight mass spectroscopy (MALDI-TOF MS). Colonies with differing
morphology were always picked and identiﬁed in this way.
PCR was used as a screening method before putative ESBL producers were subjected to WGS. Primers
for multiplex PCR as performed previously were used to identify the three most common CTX-M groups:
group 1, group 2, and group 9 (30). PCR was carried out only on isolates which had grown either on ESBL
agar or from within the zones of cefpodoxime on nonselective UTI agar. PCR amplimers were visualized
using 1% agarose gel electrophoresis.
Toothpicking experiments. In order to characterize the cefotaxime-sensitive population of E. coli
within stool samples containing CTX-M-positive post-travel E. coli, a representative collection of post-
travel stool samples were subjected to toothpicking experiments. Oxoid UTI brilliance agar was used to
culture E. coli (pink colonies) directly from stool samples. A sterile wire was used to pick individual E. coli
colonies from the chromogenic plate. Each colony was then lightly “scored” (2 to 3 mm) onto antibiotic-
free LB agar and onto LB agar containing cefotaxime (4 g/ml). One hundred colonies were picked from
each stool sample tested.
Isolates which grew on the antibiotic-free plate but failed to grow on the cefotaxime plate were
enumerated.
Whole-genome sequencing of isolates. Automated DNA extraction and whole-genome sequenc-
ing were undertaken by MicrobesNG at the University of Birmingham. Sequencing was performed using
HiSeq 2500 with 250-bp paired-end reads. QC was performed using QUAST (31). All isolates were
assembled using SPAdes (32) and annotated using Prokka (33).
Bioinformatic analyses. All sequenced E. coli isolates were subjected to analysis, by determining the
multilocus sequence type (MLST) (34). The E. coli Achtman MLST scheme (https://enterobase.warwick.ac
.uk/species/index/ecoli) of each strain was determined by inputting contig ﬁles and running the mlst
program () (35). The E. coli phylogenetic group was derived MLST data, as previously described (36).
Identifying E. coli clones from WGS data. Illumina sequence reads and assembled draft genomes
were used to determine the phylogenetic relationships of selected strains. In addition to obtaining the
MLST of each E. coli strain in the study, a core genome alignment of all strains was also undertaken, using
Parsnp (37).
Further SNP typing was undertaken to ascertain the relationship between identical STs (i.e., the
number of SNPs between E. coli strains). Snippy was used to ﬁnd SNPs between a chosen reference
genome and a set of sequence reads, thus creating a core genome SNP alignment, as described at
https://github.com/tseemann/snippy. SNP distances between each isolate in the phylogeny were deter-
mined using snp-dists, which produces an output in the form of a table matrix (https://github.com/
tseemann/snp-dists).
Ethical approval. This study was approved by the South Birmingham Research Ethics Committee
(reference 15/WM/0037).
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SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.02408-18.
TABLE S1, DOCX ﬁle, 0.1 MB.
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